Parkinson’s Disease: Debunking an old theory
A group of structures deep inside the brain are thought to be responsible for the progression of Parkinson’s disease. These structures, known as the basal ganglia, play an important role in coordinating movement via two opposing motor pathways: the ‘indirect pathway’ which suppresses movement, and the ‘direct pathway’ which promotes movement. It has been reported that overactivation of the indirect pathway and underactivation of the direct pathway lead to the motor impairments associated with Parkinson’s disease (Albin et al., 1989; Bergman et al., 1990; Gerfen et al., 1990).
Previous studies investigating the cellular mechanisms that cause these abnormalities have largely focused on spiny projection neurons (SPNs for short), a group of cells found in a basal ganglia structure known as the striatum. These cells express one of two types of dopamine receptors called D1 and D2. SPNs expressing D1 are frequently referred to as the origin of the direct pathway, whereas SPNs expressing D2 are referred to as the origin of the indirect pathway. These pathways then pass this signal between multiple structures of the basal ganglia until they reach a group of cells known as the output nuclei.
The striatum receives most of its dopamine from an area in the brain that degenerates in Parkinson’s disease. This loss in dopamine is thought to reduce the activity of D1-SPNs and increase the activity of D2-SPNs, causing neurons in the striatum to fire at different rates: this is predicted to drive the excessive activity of the indirect pathway and reduced activity of the direct pathway, which leads to pathological activity throughout the basal ganglia (Gerfen and Surmeier, 2011; Figure 1A). This hypothesis is known as the ‘rate model’ and has had a huge influence on the field of Parkinson’s disease. Yet, there has been limited in vivo evidence showing the firing rates of SPNs changing, particularly from human patients.

Investigating the origin of cellular features associated with Parkinson’s disease.
(A) Neurons in the striatum express the D1 and D2 receptors for the neurotransmitter dopamine. The rate model predicts that the loss of dopamine in Parkinson’s disease decreases the activity of cells expressing the D1 receptor, increases the activity of cells expressing the D2 receptor (left), and increases the oscillatory activity of both D1 and D2 expressing neurons (right). These changes in activity are thought to alter the direct (turquoise) and indirect (purple) signals that D1-neurons and D2-neurons send to other structures in the basal ganglia. It is thought that this causes downstream neurons in the output nuclei of the basal ganglia to fire faster, more synchronously and with more oscillations – the pathophysiology commonly found in patients with Parkinson’s disease. (B) Valsky et al. tested this model on human patients with Parkinson’s disease and could not find any evidence of neurons in the striatum changing their firing rates or patterns of activity. This suggests that the neurological features associated with Parkinson’s disease do not stem from the striatum (as predicted by the rate model) but instead may originate downstream from the striatum (highlighted in yellow), in other structures of the basal ganglia.
Image credit: Teresa Spix.
Now, in eLife, Marc Deffains (University of Bordeaux) and colleagues – including Dan Valsky (Hebrew University of Jerusalem) as first author – report experiments investigating the firing rates of SPNs in patients with Parkinson’s disease (Valsky et al., 2020). The team were able to gather data from human patients who were undergoing a surgical procedure that implants electrodes into deep regions of the brain. Valsky et al. found that the firing rates of SPNs in patients with Parkinson’s disease were no different than expected values found in healthy non-human primates. Further computational analysis, clustering the different firing rates detected, was unable to identify two distinct populations of neurons that could represent overactive D2-SPNs and underactive D1-SPNs.
These results were in contrast to the only other human study which supports the predictions made by the rate model (Singh et al., 2016). However, both studies used a different method to isolate and analyze the activity of neurons. Valsky et al. applied strict criteria to ensure that the firing rates recorded only came from well-isolated, stationary single units. This minimizes the chance of other factors, such as noise from movement or signals from damaged cells, interfering with the firing rates being measured. Valsky et al. showed that when these criteria were not in place, they were able to replicate the changes in activity reported in the previous study, but argued that this is a spurious conclusion.
The fact that Valsky et al. were not able to find evidence for the rate model within the striatum was not entirely unexpected, as the exceptions and limitations of this model have become increasingly documented (Obeso and Lanciego, 2011). Other models have proposed that the abnormalities observed in the basal ganglia arise from neurons changing their patterns of activity to fire more irregularly or with increased oscillations (Nelson and Kreitzer, 2014). But when Valsky et al. searched their data for these other patterns of activity, they could not detect any of these features in the striatal neurons of patients with Parkinson’s disease (Figure 1B).
These findings raise a lot of questions about the role the striatum plays in the motor impairments associated with Parkinson’s disease. However, two critical variables that were not addressed in this study are synchrony (non-oscillatory), and total neuron recruitment within the striatum. When multiple SPNs fire simultaneously, this relays a more powerful signal to downstream areas of the brain than if SPNs are activated independently. Therefore, if dopamine depletion enabled more D2-SPNs to activate simultaneously, or in greater numbers, this could lead to increase indirect pathway output from the striatum. However, the techniques used to record neuronal activity in this study means it is not possible to determine whether this change occurred.
These findings highlight the need for a critical reassessment of long-standing assumptions about the cellular mechanisms involved in the onset of Parkinson’s disease. Even if this study does not completely rule out the striatum as a source of basal ganglia abnormalities in this condition, it narrows down the types of changes that might be responsible. It also emphasizes the roles of brain structures that are traditionally considered to be ‘downstream’ of the striatum in generating the neuronal defects associated with Parkinson’s disease (Figure 1B). Furthermore, this work provides a valuable, rigorously curated data set which will be beneficial to the field.
References
-
The functional anatomy of basal ganglia disordersTrends in Neurosciences 12:366–375.https://doi.org/10.1016/0166-2236(89)90074-X
-
Modulation of striatal projection systems by dopamineAnnual Review of Neuroscience 34:441–466.https://doi.org/10.1146/annurev-neuro-061010-113641
-
Reassessing models of basal ganglia function and dysfunctionAnnual Review of Neuroscience 37:117–135.https://doi.org/10.1146/annurev-neuro-071013-013916
-
Past, present, and future of the pathophysiological model of the basal gangliaFrontiers in Neuroanatomy 5:39.https://doi.org/10.3389/fnana.2011.00039
Article and author information
Author details
Publication history
Copyright
© 2020, Spix and Gittis
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,110
- views
-
- 184
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
- Medicine
Background:
It has been reported that loss of PCBP2 led to increased reactive oxygen species (ROS) production and accelerated cell aging. Knockdown of PCBP2 in HCT116 cells leads to significant downregulation of fibroblast growth factor 2 (FGF2). Here, we tried to elucidate the intrinsic factors and potential mechanisms of bone marrow mesenchymal stromal cells (BMSCs) aging from the interactions among PCBP2, ROS, and FGF2.
Methods:
Unlabeled quantitative proteomics were performed to show differentially expressed proteins in the replicative senescent human bone marrow mesenchymal stromal cells (RS-hBMSCs). ROS and FGF2 were detected in the loss-and-gain cell function experiments of PCBP2. The functional recovery experiments were performed to verify whether PCBP2 regulates cell function through ROS/FGF2-dependent ways.
Results:
PCBP2 expression was significantly lower in P10-hBMSCs. Knocking down the expression of PCBP2 inhibited the proliferation while accentuated the apoptosis and cell arrest of RS-hBMSCs. PCBP2 silence could increase the production of ROS. On the contrary, overexpression of PCBP2 increased the viability of both P3-hBMSCs and P10-hBMSCs significantly. Meanwhile, overexpression of PCBP2 led to significantly reduced expression of FGF2. Overexpression of FGF2 significantly offset the effect of PCBP2 overexpression in P10-hBMSCs, leading to decreased cell proliferation, increased apoptosis, and reduced G0/G1 phase ratio of the cells.
Conclusions:
This study initially elucidates that PCBP2 as an intrinsic aging factor regulates the replicative senescence of hBMSCs through the ROS-FGF2 signaling axis.
Funding:
This study was supported by the National Natural Science Foundation of China (82172474).
-
- Immunology and Inflammation
- Medicine
Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.